Anti-CD38 Antibody Safe, Effective in Immune Thrombocytopenia

(MedPage Today) — Treatment with the investigational anti-CD38 monoclonal antibody mezagitamab was found to be safe and significantly increased platelet counts in patients with persistent or chronic immune thrombocytopenia (ITP), according to a randomized phase II trial…